<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963416</url>
  </required_header>
  <id_info>
    <org_study_id>UOR-0001</org_study_id>
    <nct_id>NCT01963416</nct_id>
  </id_info>
  <brief_title>Effects of Fruit Consumption on Risk Factors of Chronic Disease</brief_title>
  <official_title>A Randomized Controlled, Crossover in Design, Double Blind Clinical Trial Investigating the Effects of Whole Versus Processed Fruit Consumption on Risk Factors for Chronic Disease and Performance Indicators.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Reading</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Reading</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute, randomized, placebo controlled, double blind, postprandial crossover study in male&#xD;
      subjects. 4 intervention arms consisting of control, orange juice, whole orange, and&#xD;
      processed whole orange to determine the effect of the interventions on the primary measure of&#xD;
      flow mediated dilatation (FMD) and additional biomarkers of health. The study will also&#xD;
      identify and quantify the main micronutrients and phytochemicals in each of the products and&#xD;
      will identify and quantify the main micronutrients and phytochemicals and their metabolites&#xD;
      in the subjects' plasma and/or urine. A subset of the study population (n=24) will be invited&#xD;
      to participate in an additional arm of the main study which is summarised below.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilation</measure>
    <time_frame>change in Flow Mediated Dilation response between baseline and 6 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postprandial plasma glucose</measure>
    <time_frame>change in glucose from baseline to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial insulin</measure>
    <time_frame>change from baseline to 2 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>global cognitive function</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postprandial non-esterified fatty acids</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postprandial triacylglycerol</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total HDL/LDL</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory status (IL1-beta; IL2; IL6; IL10; IFN-gamma; TNF-alpha; CRP)</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL oxidation</measure>
    <time_frame>change from baseline to 6h</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Plasma flavanone metabolites</measure>
    <time_frame>change from baseline to 6 hours</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Vascular Stiffness</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>macro- and micro-nutrient matched control (240 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Orange juice</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>commercial orange juice (240 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>whole orange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>whole orange fruit (240 ml)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>processed whole orange</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>processed whole orange (240 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>macro- and micro-nutrient matched control (240 ml)</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Orange juice</intervention_name>
    <arm_group_label>Orange juice</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>whole orange fruit</intervention_name>
    <arm_group_label>whole orange</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Processed whole orange</intervention_name>
    <arm_group_label>processed whole orange</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males due to potential hormonal fluctuations in female subjects&#xD;
&#xD;
          -  Aged 30-65years&#xD;
&#xD;
          -  Fasting total cholesterol in the upper half of the normal range (6.0-8.0 mmol/l) or&#xD;
             triacylglycerol &gt;0.8 mmol/l or a BMI 25-32 kg/m2.&#xD;
&#xD;
          -  Not having suffered a myocardial infarction/stroke in the past 12 months&#xD;
&#xD;
          -  Not diabetic (diagnosed or fasting glucose &gt; 7 mmol/l) or suffer from other endocrine&#xD;
             disorders&#xD;
&#xD;
          -  Not suffering from renal or bowel disease or have a history of choleostatic liver or&#xD;
             pancreatitis&#xD;
&#xD;
          -  Not on drug treatment for hyperlipidaemia, hypertension, inflammation or&#xD;
             hypercoagulation&#xD;
&#xD;
          -  No history of alcohol misuse&#xD;
&#xD;
          -  Not planning or on a weight reducing regime&#xD;
&#xD;
          -  Not taking any fish oil, fatty acid or vitamin and mineral supplements&#xD;
&#xD;
          -  Non smokers&#xD;
&#xD;
          -  Not suffering from depression as indicated by the Brief Symptom Inventory (Appendix&#xD;
             11).&#xD;
&#xD;
          -  Not suffering from mild cognitive impairment or dementia according to the MMSE (score&#xD;
             â‰¥ 25).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females&#xD;
&#xD;
          -  Medication for hypertension, hyperlipidaemia, inflammation or hypercoagulation&#xD;
&#xD;
               -  Hypertension - ACE Inhibitors (e.g. Captopril, Cilazapril), Angiotensin Receptor&#xD;
                  Blockers (Valsartan), Calcium Channel Blockers (Amlodipine, Nicardipine),&#xD;
                  Diuretics (Chlortalidone) or Beta blockers (Sotalol, Bisoprolol).&#xD;
&#xD;
               -  Cholesterol lowering (Pravastatin, Simuvustatin)&#xD;
&#xD;
               -  Anticoagulants (Warfarin)&#xD;
&#xD;
               -  Inflammation - NSAID's (Tiaprofenic acid, Sulindac, Ibuprofen),&#xD;
                  Corticosteroids(Betamethasone)&#xD;
&#xD;
          -  Strict vegetarians&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Those on or planning a weight reducing regime&#xD;
&#xD;
          -  Blood glucose, haemaglobin or liver enzymes outside of the normal range&#xD;
&#xD;
          -  Unable to consume study meals&#xD;
&#xD;
          -  Those suffering from depression as indicated by the Brief Symptom Inventory (Appendix&#xD;
             11).&#xD;
&#xD;
          -  Those suffering from mild cognitive impairment or dementia as indicated by the MMSE&#xD;
             (score &lt; 25).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Reading</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 9AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <last_update_submitted>October 11, 2013</last_update_submitted>
  <last_update_submitted_qc>October 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Reading</investigator_affiliation>
    <investigator_full_name>Jeremy Paul Edward Spencer</investigator_full_name>
    <investigator_title>Professor of Nutritional Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Micronutrients</mesh_term>
    <mesh_term>Trace Elements</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

